Keywords: Liver, Treatment, Targeted Therapy, Immunotherapy, Prognostic Prediction ·One-hundred and sixty-six patients (55.6±10.4 years) treated with lenvatinib plus anti-PD-1 antibody were included in training cohort and 77 patients (55.4±10.7 years) treated with lenvatinib or bevacizumab plus anti-PD-1 antibody were included in validation cohort. Based on independent risk factors (Gender, intRatumoral fAt, enhancing tumor caPsule, gross growtH type and CRAFITY Score) identified by the multivariate analysis, a novel prognostic tool named GRAPH-CRAFITY Score was developed to predict OS. GRAPH-CRAFITY Score by integrating Gender, MR features and laboratory tests is an effective and user-friendly tool to predict OS of HCC patients treated with targeted therapy and immunotherapy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords